Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis.

Standard

Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. / Kröger, Nicolaus; Zabelina, Tatjana; Schieder, Heike; Panse, Jens; Ayuk, Francis; Stute, Norbert; Fehse, Natalja; Waschke, Olga; Fehse, Boris; Kvasnicka, Hans Michael; Thiele, Jürgen; Zander, Axel.

in: BRIT J HAEMATOL, Jahrgang 128, Nr. 5, 5, 2005, S. 690-697.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Kröger, N, Zabelina, T, Schieder, H, Panse, J, Ayuk, F, Stute, N, Fehse, N, Waschke, O, Fehse, B, Kvasnicka, HM, Thiele, J & Zander, A 2005, 'Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis.', BRIT J HAEMATOL, Jg. 128, Nr. 5, 5, S. 690-697. <http://www.ncbi.nlm.nih.gov/pubmed/15725091?dopt=Citation>

APA

Kröger, N., Zabelina, T., Schieder, H., Panse, J., Ayuk, F., Stute, N., Fehse, N., Waschke, O., Fehse, B., Kvasnicka, H. M., Thiele, J., & Zander, A. (2005). Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. BRIT J HAEMATOL, 128(5), 690-697. [5]. http://www.ncbi.nlm.nih.gov/pubmed/15725091?dopt=Citation

Vancouver

Bibtex

@article{18518515fe1d450ab80a3d6e1d67ff2d,
title = "Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis.",
abstract = "A prospective pilot study was performed to evaluate the effect of reduced-intensity conditioning with busulphan (10 mg/kg), fludarabine (180 mg/qm) and anti-thymocyte globulin followed by allogeneic stem cell transplantation from related (n = 8) and unrelated donors (n = 13) in 21 patients with myelofibrosis. The median age of the patients was 53 years (range, 32-63). No primary graft failure occurred. The median time until leucocyte (>1.0 x 10(9)/l) and platelet (>20 x 10(9)/l) engraftment was 16 (range, 11-26) and 23 d (range, 9-139) respectively. Complete donor chimaerism on day 100 was seen in 20 patients (95%). Acute graft-versus-host disease (GvHD) grades II-IV and III/IV occurred in 48% and 19% of cases and 55% of the patients had chronic GvHD. Treatment-related mortality was 0% at day 100 and 16% [95% confidence interval (CI): 0-32%] at 1 year. Haematological response was seen in 100% and complete histopathological remission was observed in 75% of the patients and 25% of the patients showed partial histopathological remission with a continuing decline in the grade of fibrosis. After a median follow-up of 22 months (range, 4-59), the 3-year estimated overall and disease-free survival was 84% (95% CI: 67-100%).",
author = "Nicolaus Kr{\"o}ger and Tatjana Zabelina and Heike Schieder and Jens Panse and Francis Ayuk and Norbert Stute and Natalja Fehse and Olga Waschke and Boris Fehse and Kvasnicka, {Hans Michael} and J{\"u}rgen Thiele and Axel Zander",
year = "2005",
language = "Deutsch",
volume = "128",
pages = "690--697",
journal = "BRIT J HAEMATOL",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS

TY - JOUR

T1 - Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis.

AU - Kröger, Nicolaus

AU - Zabelina, Tatjana

AU - Schieder, Heike

AU - Panse, Jens

AU - Ayuk, Francis

AU - Stute, Norbert

AU - Fehse, Natalja

AU - Waschke, Olga

AU - Fehse, Boris

AU - Kvasnicka, Hans Michael

AU - Thiele, Jürgen

AU - Zander, Axel

PY - 2005

Y1 - 2005

N2 - A prospective pilot study was performed to evaluate the effect of reduced-intensity conditioning with busulphan (10 mg/kg), fludarabine (180 mg/qm) and anti-thymocyte globulin followed by allogeneic stem cell transplantation from related (n = 8) and unrelated donors (n = 13) in 21 patients with myelofibrosis. The median age of the patients was 53 years (range, 32-63). No primary graft failure occurred. The median time until leucocyte (>1.0 x 10(9)/l) and platelet (>20 x 10(9)/l) engraftment was 16 (range, 11-26) and 23 d (range, 9-139) respectively. Complete donor chimaerism on day 100 was seen in 20 patients (95%). Acute graft-versus-host disease (GvHD) grades II-IV and III/IV occurred in 48% and 19% of cases and 55% of the patients had chronic GvHD. Treatment-related mortality was 0% at day 100 and 16% [95% confidence interval (CI): 0-32%] at 1 year. Haematological response was seen in 100% and complete histopathological remission was observed in 75% of the patients and 25% of the patients showed partial histopathological remission with a continuing decline in the grade of fibrosis. After a median follow-up of 22 months (range, 4-59), the 3-year estimated overall and disease-free survival was 84% (95% CI: 67-100%).

AB - A prospective pilot study was performed to evaluate the effect of reduced-intensity conditioning with busulphan (10 mg/kg), fludarabine (180 mg/qm) and anti-thymocyte globulin followed by allogeneic stem cell transplantation from related (n = 8) and unrelated donors (n = 13) in 21 patients with myelofibrosis. The median age of the patients was 53 years (range, 32-63). No primary graft failure occurred. The median time until leucocyte (>1.0 x 10(9)/l) and platelet (>20 x 10(9)/l) engraftment was 16 (range, 11-26) and 23 d (range, 9-139) respectively. Complete donor chimaerism on day 100 was seen in 20 patients (95%). Acute graft-versus-host disease (GvHD) grades II-IV and III/IV occurred in 48% and 19% of cases and 55% of the patients had chronic GvHD. Treatment-related mortality was 0% at day 100 and 16% [95% confidence interval (CI): 0-32%] at 1 year. Haematological response was seen in 100% and complete histopathological remission was observed in 75% of the patients and 25% of the patients showed partial histopathological remission with a continuing decline in the grade of fibrosis. After a median follow-up of 22 months (range, 4-59), the 3-year estimated overall and disease-free survival was 84% (95% CI: 67-100%).

M3 - SCORING: Zeitschriftenaufsatz

VL - 128

SP - 690

EP - 697

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 5

M1 - 5

ER -